Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05545891 · ClinicalTrials.gov registry record · Phase 2
Aripiprazole in Body Focused Repetitive Behaviors
A Phase 2 study, sponsored by University of Chicago.
- Not yet
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT05545891 is a Phase 2 study that has not yet begun recruiting, run by University of Chicago. The registered enrollment target is 100 participants.
The verdict
NCT05545891, a Phase 2 study, has not yet begun recruiting, sponsored by University of Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are randomly assigned to the aripiprazole arm and are eligible to participate in the study, they will begin by taking 5mg once daily of aripiprazole for two weeks, then 10mg once daily for the remaining three weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either aripiprazole or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.
Interventions
- DRUG Placebo
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05545891
The ClinicalTrials.gov registry entry for NCT05545891 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05545891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05545891 about?
NCT05545891 is a clinical study titled "Aripiprazole in Body Focused Repetitive Behaviors". This study is 6 weeks long and involves subjects taking aripiprazole or placebo. If they are randomly assigned to the aripiprazole arm and are eligible to participate in the study, they will begin by taking 5mg once daily of aripiprazole for two weeks, then 10mg once daily for the remaining three we...
What is the current status of trial NCT05545891?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-06. Estimated completion is 2027-12.
What interventions are being tested in trial NCT05545891?
The interventions under investigation include: Placebo (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT05545891?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.